CPHI
AMEXChina Pharma Holdings Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.75+0.16 (+27.36%)
2026-03-162026-06-17
News · 26 weeks8-100%
2025-12-212026-06-14
Mix490d
- Other2(50%)
- SEC Filings2(50%)
Latest news
25 items- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market ActivityHAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 12 and 13, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity. About China Pharma Holdings, Inc. China Pharma Holdin
- SECSEC Form 10-K filed by China Pharma Holdings Inc.10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form NT 10-K filed by China Pharma Holdings Inc.NT 10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form DEF 14A filed by China Pharma Holdings Inc.DEF 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form PRE 14A filed by China Pharma Holdings Inc.PRE 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Holdings Inc. Announces 1-for-10 Reverse Stock SplitHAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401. The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by
- SECSEC Form 10-K filed by China Pharma Holdings Inc.10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with StreetervilleHAIKOU, China, Dec. 18, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced successful completion of all redemptions under its Convertible Promissory Note agreement (the "Convertible Promissory Note") with Streeterville Capital, LLC as of December 11, 2024. This marks a significant step in strengthening the company's financial position and reflects its commitment to sound fiscal management. The Convertible Promissory Note was originally issued on November 17, 2021, with a principal amount of $5,250,000. Following a
- SECChina Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form 424B5 filed by China Pharma Holdings Inc.424B5 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- PRChina Pharma Announces the Entry of "At-The-Market" Equity OfferingHAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing"). The shares will be offered pursuant to a certain Securities Purchase Agreement (the "SPA") the Company entered into with certain investor (the "Investor") on December 12, 2024. Pursuant to the SPA, the Investor agrees t
- SECSEC Form 10-Q filed by China Pharma Holdings Inc.10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
- SECSEC Form DEF 14A filed by China Pharma Holdings Inc.DEF 14A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)
CPHI FAQ
5 questionsWhat does China Pharma Holdings Inc. do?
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to...Where does CPHI stock trade?
China Pharma Holdings Inc. (CPHI) is listed on AMEX.What sector and industry is CPHI in?
China Pharma Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to CPHI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CPHI side-by-side with any of them on Quantisnow.How can I track CPHI on Quantisnow?
Quantisnow aggregates China Pharma Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CPHI to receive live email and push alerts on every new disclosure.